The FDA has approved a trial to test BioCardia‘s (OTC:BCDA) CardiAMP cell therapy in chronic myocardial ischemia patients with refractory angina.
The San Carlos, Calif.-based company could enroll up to 343 patients in the pivotal trial, which is designed to support benefit claims for the cell therapy product without the need for a second confirmatory trial.
Get the full story at our sister site, Drug Delivery Business News.
The post BioCardia wins FDA nod for chronic myocardial ischemia pivotal trial appeared first on MassDevice.
from MassDevice http://ift.tt/2rVZ5rQ
Cap comentari:
Publica un comentari a l'entrada